Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 1525 Print this page  Email this page Small font size Default font size Increase font size
Year : 2007  |  Volume : 22  |  Issue : 2  |  Page : 41-46

A new method for radiolabeling of alendronate with Tc-99m for bone scintigraphy

Institute of Nuclear Medicine and Allied Sciences, Brig. SK Mazumdar Marg, Delhi, India

Correspondence Address:
Aseem Bhatnagar
Institute of Nuclear Medicine and Allied Sciences, Brig. SK Mazumdar Marg, Delhi - 110 054
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Objective: Tc-99m MDP and Tc-99m HEDP are the conventional bone scintigraphy agents widely used for the last 30 years. Since then, a variety of new phosphonates including alendronate have replaced the older ones because of higher efficacy in bone disorders. In the present study we propose a method to radiolabel alendronate with Tc-99m and compare it with conventionally available agent (Tc-99m MDP) for bone imaging. Methods: Ready to use alendronate kits were produced using stannous chloride reduction method. The kit underwent in vitro and in vivo quality control tests in animals followed by human trial in more than 35 subjects. In many cases, both Tc-99m alendronate and Tc-99m MDP scans were done. Results: More than 98% radiolabeling was consistently achieved. Serum studies showed 47% protein binding and stability of the preparation up to 24 h. Animal biodistribution studies and blood clearance data supports similar bone uptake and faster blood clearance as compared to Tc-99m MDP. Bone scintigraphy with Tc-99m alendronate in humans suggests acceptable bone to soft tissue ratio at 90-120 min. Conclusions: The proposed method of radiocomplexation of alendronate is a viable option for preparing this radiopharmaceutical. Tc-99m alendronate gives acceptable images at 90-120 min post injection compared to 3-4 hrs with Tc-99m MDP. It has the potential to become an important bone-imaging agent because of easy availability, cost-effectiveness and the fact that MDP is now obsolete and may not be available easily as a drug.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded173    
    Comments [Add]    

Recommend this journal